UNSPSC 51321608: Sodium tetradecyl sulfate

An injectable sterile nonpyrogenic solution for intravenous use as a sclerosing agent.

UNSPSC 51321608 Sodium tetradecyl sulfate is a Commodity code that covers pharmaceutical active ingredients and specialty chemical agents used in medical formulations, though recent state and local solicitations tagged with this code do not show procurement specifically for sodium tetradecyl sulfate; instead, they reflect broader pharmaceutical and medication supply activity. State and local governments acquiring under this code's broader family include municipal fire-rescue services, state health agencies, and cooperative purchasing alliances serving multi-state healthcare systems. The Tampa Fire Rescue advanced life support medications procurement (City of Tampa, sealed-bid, due April 8, 2026) and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) generic pharmaceuticals RFP (response due March 26, 2026) represent the mix of direct municipal procurement and cooperative purchasing vehicles through which state and local bodies source pharmaceutical inventory. The Texas Health and Human Services Commission RFI issued in early April 2026 signals state-level interest in restructuring pharmacy benefit channels through direct-to-manufacturer relationships, though that initiative remains in information-gathering phase and does not yet reflect formal purchasing commitments.

Activity under this code spans Florida (Tampa municipal procurement), Minnesota and Oregon (via MMCAP cooperative), and Texas (state HHS agency), with additional representation in participating MMCAP member states. The Tampa solicitation (Bid No. 26-P-00188) targets four specific advanced life support medications with firm pricing, 9+ month shelf life, and delivery within 10 days, with a $40,000 estimated contract value and SLBE-sheltered market designation including 5 percent bid discount. The MMCAP RFP establishes multiple contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers effective July 1, 2026, with price competitiveness weighted at 75 percent of evaluation and vendors required to maintain cGMP and DSCSA compliance, minimum $5 million commercial general liability insurance, and one-year product expiration dates. No recent opportunities show direct procurement specifically for sodium tetradecyl sulfate as a standalone active ingredient.